Pancreatic Cancer Drug Daraxonrasib Extends Survival in Phase 3 Trial
A phase 3 trial has shown that the drug daraxonrasib nearly doubles the median overall survival for patients with previously treated metastatic pancreatic cancer. The trial involved 500 patients and extended survival to 13.2 months compared to 6.7 months with standard chemotherapy. Despite not being a cure, the drug represents a significant advancement in treating a cancer with a high mortality rate. Daraxonrasib targets the KRAS gene, which is mutated in over 90% of pancreatic tumors. The drug is not yet approved, but an expanded access protocol allows certain patients to receive it outside of clinical trials. 
